Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isg15 controls p53 stability and functions.

Yi-Fu Huang1, Sheena Wee1, Jayantha Gunaratne1

  • 1Institute of Molecular and Cell Biology; A*STAR; Singapore.

Cell Cycle (Georgetown, Tex.)
|May 22, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HBx interacts with the host YBX3 protein and up-regulates its expression to mediate efficient Hepatitis B viral replication.

Frontiers in cellular and infection microbiology·2026
Same author

DP103 as a critical modulator of Wnt signaling and cancer stemness: implications for precision treatment in triple negative breast cancer.

Cell death & disease·2026
Same author

A cross-talk between p16High senescence and cellular reprogramming.

Clinical science (London, England : 1979)·2026
Same author

Uncovering shared and tissue-specific molecular adaptations to intermittent fasting in liver, brain, and muscle.

eLife·2026
Same author

FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling.

Nature communications·2026
Same author

Betulin inhibits titanium particle-induced osteolysis and attenuates RANKL-associated osteoclastogenesis by suppressing the MAPK pathway.

European journal of pharmacology·2026
Same journal

Circular RNA circ_0001829 attenuates G2/M arrest to promote hepatocyte proliferation by sponging miR-3095-3p following liver injury.

Cell cycle (Georgetown, Tex.)·2026
Same journal

Identification of PGF+ endothelial cells associated with plaque instability in carotid atherosclerosis by scRNA-seq and RNA-seq analysis.

Cell cycle (Georgetown, Tex.)·2026
Same journal

BMSCs-derived exosomal miR-196a-5p promotes macrophage M2 polarization and osteogenesis in postmenopausal osteoporosis through regulating Rspo2/Wnt/β-catenin signaling.

Cell cycle (Georgetown, Tex.)·2026
Same journal

MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.

Cell cycle (Georgetown, Tex.)·2026
Same journal

OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.

Cell cycle (Georgetown, Tex.)·2026
Same journal

MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.

Cell cycle (Georgetown, Tex.)·2026
See all related articles

The study reveals that ISGylation, a process involving the protein ISG15, targets and degrades the tumor suppressor p53. This ISG15-dependent degradation offers a new drug discovery pathway for controlling p53 levels.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tumor suppressor p53 function is tightly regulated by its degradation.
  • Ubiquitin-dependent pathways are the primary known mechanisms for p53 degradation.

Purpose of the Study:

  • To investigate alternative pathways for p53 degradation.
  • To explore the role of ISG15 conjugation (ISGylation) in p53 regulation.

Main Methods:

  • Western blotting to detect ISGylated p53.
  • Proteasome activity assays.
  • Analysis of p53 activity in Isg15-deficient cells.

Main Results:

  • p53 is covalently modified by ISG15 at two sites.
  • ISGylated p53 is degraded by the 20S proteasome.
Keywords:
Isg15apoptosisp53protein degradation misfolded protein

Related Experiment Videos

  • ISGylation specifically targets misfolded, dominant-negative p53 variants.
  • Loss of ISG15 in cells suppresses p53 activity and function.

    • Conclusions:

    • ISGylation represents a novel, ubiquitin-independent pathway for p53 degradation.
    • This ISG15-mediated degradation mechanism offers a new target for therapeutic intervention in cancer.
    • Targeting the ISG15-p53 interaction could be a promising strategy for drug discovery.